Pfizer Inc. (ETR:PFE)
Germany
· Delayed Price · Currency is EUR | Market Cap | 142.60B |
| Revenue (ttm) | 61.46B |
| Net Income (ttm) | 7.76B |
| Shares Out | n/a |
| EPS (ttm) | 1.36 |
| PE Ratio | 18.38 |
| Forward PE | n/a |
| Dividend | 1.58 (6.33%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 36,886 |
| Average Volume | 69,441 |
| Open | 24.73 |
| Previous Close | 24.87 |
| Day's Range | 24.63 - 24.99 |
| 52-Week Range | 23.25 - 29.50 |
| Beta | 0.57 |
| RSI | 48.73 |
| Earnings Date | Feb 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 8.77% compared to the previous year's $58.50 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
According to multiple media reports on Thursday, Pfizer Inc. (NYSE: PFE) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez. In April 2024, the FDA a...
Pfizer: Investors Won't Stick Around Forever
Pfizer board approves marketing and supply agreement with Mylan Pharmaceuticals for Ativan and Pacitane in India
Pfizer’s Board of Directors, in a meeting held from February 20 to February 21, 2025, approved a strategic Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited. The agreement focu...
Pfizer said to be discontinuing Roche-partnered hemophilia therapy Beqvez
Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends
The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annuali...
10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers
Before January 31, 2025, my REaders mentioned 40 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about the ReFa/Ro. ...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Why Pfizer's Stock Price Isn't Reflecting Its True Value
Pfizer Stock's Upside Got Bigger
Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.
Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.
Watch CNBC's full interview with Pfizer CEO Albert Bourla
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for ...
3 Things You Need to Know If You Buy Pfizer Today
Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell
I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 billi...
Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
Does the Length of a Super Bowl Ad Matter?
This year, 30-second commercials in the Super Bowl went for more than $8 million; however, for some brands, that simply wasn't enough time. Dunkin', Pfizer, T-Mobile, Uber Eats, and TurboTax were some...
The Big 3: AMSC, PFE, GOLD
Alan Knuckman turns to stocks he believes aren't as renowned as their peers. He explains why he's watching American Superconductor (ASMC), Pfizer (PFE), and Barrick Gold (GOLD) for today's Big 3.
Pfizer reports positive results for Talzenna/Xtandi combo
Pfizer Inc (PFE) Announces Positive Phase 3 Results for TALZENNA in Combination with XTANDI
Pfizer Inc (PFE) Announces Positive Phase 3 Results for TALZENNA in Combination with XTANDI
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic ...
Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (en...
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in...
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Philadelphia, Pennsylvania--(Newsfile Corp. - February 13, 2025) - Berger Montague advises shareholders of Pfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE) about an investigation into Pfizer's Boar...